Figure 11

The morphological cell changes showing inhibitory activity of the synthesized PVP SeNPs against liver carcinoma (HepG2) cell line (A) control non-treated and (B) treated; breast carcinoma (MCF-7) cell line (C) control non-treated and (D) treated; colorectal carcinoma (Caco2) cell line (E) control non-treated and (F) treated; cervix carcinoma (HeLa) cell line (G) control non-treated and (H) treated; prostate carcinoma (PC3) cell line (I) control non-treated & (J) treated.